Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hey hey, this is Meghana. Today, we talk about major restructuring at Editas Medicine, see a new commercialization strategy from Ionis, and learn what people in Trump’s orbit think of GLP-1 drugs.